BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal positive sentiment: strong projections for Attruby, a $500M share repurchase, and positive feedback on infigratinib. The company is gearing up for multiple product launches and has a solid market strategy. Despite some vague responses, the overall outlook is promising, with a focus on growth and shareholder returns. The market cap suggests moderate volatility, leading to a positive stock price movement prediction.
Key Financial Performance
Attruby net product revenue $180.6 million this quarter, representing a 24% growth from the last quarter and a 392% growth year-on-year. The growth is attributed to commercial momentum, expanded sales teams, accelerating new patient starts, and first-line share gains.
Total revenues $194.5 million for the first quarter of 2026, compared to $116.6 million for the same period of 2025. This increase of $77.9 million was primarily driven by a $143.9 million increase in Attruby net product revenue.
Royalty revenue $9.5 million, an increase of $9.3 million year-over-year, primarily earned from net product sales of BEYONTTRA in Europe and Japan.
License and services revenue $4.4 million, compared to $79.7 million for the same period last year. The decline reflects the recognition of a one-time $75 million regulatory milestone from the prior year.
Total operating expenses $290.5 million for the first quarter of 2026, compared to $218.4 million for the same period last year. The $72.1 million increase reflects investment in Attruby and preparations for upcoming launches.
SG&A expenses $163.9 million, an increase of $57.5 million compared to the same period last year, reflecting investment in commercial activities.
R&D expenses $126.6 million, an increase of $15.2 million year-over-year, driven by investments in medical affairs and CMC in support of upcoming launches.
Operating loss $106 million for the first quarter of 2026. Over the last 5 quarters, the loss from operations has narrowed by more than 50% due to operational discipline and strong execution on Attruby.
Cash position $940.2 million in cash, cash equivalents, and marketable securities at the end of the first quarter, compared to $587.5 million at the end of last year. This increase reflects a strong financial position to fund operating activities and upcoming launches.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Attruby Sales: Achieved $180.6 million in U.S. net product revenue this quarter, representing a 24% growth from the last quarter and a 392% growth year-on-year. The product is becoming a blockbuster in 2026.
Pipeline Products: Launch readiness for three first-in-class or best-in-class brands in ADH1, LGMD2I, and achondroplasia is underway. These products are expected to receive high-quality approvals and launches.
Market Share Growth: Attruby's market share in the front line has grown, becoming the second brand by volume in the space. New patient starts in the category exceeded 6,100 this quarter.
Global Expansion: Royalty revenue increased by $9.3 million, primarily from BEYONTTRA sales in Europe and Japan.
Operational Efficiency: Operating loss narrowed by more than 50% over the last 5 quarters due to disciplined OpEx management and strong Attruby execution.
Financial Position: Ended the quarter with $940.2 million in cash, providing significant runway for operations and upcoming launches.
Share Repurchase Program: Announced a $500 million share repurchase program to address the disconnect between intrinsic value and share price.
Real-World Evidence Studies: Attruby demonstrated statistically significant outcome improvements compared to competitors in real-world studies, supporting its clinical differentiation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Attruby Competition: Attruby faces significant competition from Pfizer in the front-line market. Despite growth in market share, Attruby remains behind Pfizer, which could impact its ability to dominate the market.
Regulatory and Launch Readiness: The company is heavily investing in launch readiness for three new brands (ADH1, LGMD2I, and achondroplasia). Delays or issues in regulatory approvals or launch execution could adversely affect the company's strategic objectives.
Attruby Real-World Evidence: Attruby's differentiation relies on real-world evidence studies to demonstrate its superiority over competitors. Any failure to substantiate these claims could weaken its market position.
Attruby Insurance Dynamics: Attruby's reliance on Part D insurance dynamics, which avoids annual renewal friction, is a structural advantage. However, any changes in insurance policies or patient affordability could disrupt its growth trajectory.
Attruby Market Growth: Attruby's growth is tied to its ability to increase new patient starts and first-line share gains. Failure to sustain this growth could impact revenue projections.
Pipeline Risks: The company is preparing for launches in areas with no approved therapies (e.g., LGMD2I). Any missteps in patient identification, physician education, or infrastructure setup could hinder these launches.
Financial Sustainability: The company is operating at a loss and heavily investing in R&D and SG&A. While narrowing losses, failure to achieve P&L breakeven or cash flow positivity as planned could strain financial resources.
Share Repurchase Program: The $500 million share repurchase program aims to address the disconnect between intrinsic value and share price. However, this could divert resources from operational and strategic investments if not managed carefully.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Attruby Growth and Differentiation: BridgeBio expects Attruby to continue growing past 2032, driven by clinical differentiation and economic advantages in the Part D orphan drug channel. The company is exploring real-world evidence studies to demonstrate Attruby's superiority over competitors, including tafamidis, in terms of mortality reduction and renal protective effects. Long-term efficacy and safety data from Phase III trials show sustained clinical benefits, including significant reductions in all-cause and cardiovascular mortality.
Pipeline Launch Readiness: BridgeBio is preparing for the launch of three first-in-class or best-in-class brands: ADH1, LGMD2I, and achondroplasia. The company is focused on ensuring high-quality approvals and launches, with activities including regulatory submissions and market-building exercises. The LGMD2I program has already submitted an NDA, and the ADH1 program is supported by genetic testing initiatives to identify new patients. Achondroplasia's Phase III data will be presented in the second half of 2026, with early commercial research indicating strong physician awareness.
Financial Outlook: BridgeBio expects to transition towards P&L breakeven and sustainable cash flow positivity by 2027. The company has authorized a $500 million share repurchase program to capture value for investors, supported by a strong balance sheet with $940.2 million in cash and equivalents. The financial strategy includes disciplined investment in upcoming launches and Attruby's commercial growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: BridgeBio announced a $500 million share repurchase program to address the disconnect between the company's intrinsic value and its current share price. The program aims to concentrate shareholder ownership in a portfolio with an improved risk profile. The company has previously employed share repurchases six times, yielding substantial returns for investors. The repurchase program is described as additive and opportunistic, not substitutive, and is supported by the company's strong balance sheet. The company emphasized that it will maintain sufficient liquidity to finance its clinical trials and launches while executing the buyback.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the continued acceleration of Attruby, especially in treatment-naive patients?
A:The acceleration is driven by physicians' preference for the only near-complete stabilizer on the market, Attruby's speed in showing separation from placebo, and real-world evidence supporting its effectiveness in both treatment-naive and switch patients. Additionally, increases in serum TTR levels have been associated with significant decreases in mortality.
Q:How does the tafamidis IP evolution and genericization impact the development and commercial strategy for acoramidis?
A:The clarity on Vyndamax IP provides at least 6 years of runway before generics, allowing sufficient time to reach peak share. The commercial strategy remains focused on establishing Attruby as the treatment of choice in ATTR-CM. Management is confident in Attruby's potential to become a $4 billion drug, with potential for growth even after 2032.
Q:What was the rationale behind the $500 million share repurchase program?
A:The focus is on executing the current pipeline and launches. Management believes the best use of excess capital is repurchasing shares due to the disconnect between intrinsic value and trading price. They aim to avoid diluting shareholders unnecessarily.
Q:What real-world evidence supports Attruby's differentiation versus TAF?
A:Real-world evidence shows advantages in diuretic intensification, downstream kidney effects, and mortality and hospitalization benefits. These findings align with Attruby's clinical trial results, where it outperformed tafamidis in all aspects.
Q:What feedback has been received regarding infigratinib and its commercial opportunity in achondroplasia?
A:Feedback from clinicians and caregivers has been overwhelmingly positive. Families are eager for an oral option, especially those who avoided treatment previously. Infigratinib's best-in-class profile, including proportionality data and safety, is resonating well. Management believes it can achieve over 65% market share.
Q:How is the company preparing for the limb-girdle NDA launch?
A:The company has commercial and sales leadership in place, plans to hire sales reps later this year, and has a seasoned MSL team. They are driving awareness of the Phase III data and emphasizing genetic diagnosis to ensure readiness for launch.
Q:What are the expectations for the CARDIO-TTRansform trial and its impact on the ATTR space?
A:Management expects the trial to be positive due to its strong powering. They believe stabilizers will remain first-line treatment and that combination therapies will be important for patients failing stabilizers. They are looking for a 50% reduction in hospitalization as a key metric.
Q:What patient identification efforts are being made for encaleret in ADH1?
A:Efforts include raising awareness of the disease, leveraging the ICD-10 code for targeted outreach, and family tracing due to the dominant inheritance pattern. These efforts aim to ensure patients are appropriately diagnosed and ready for therapy at launch.
Q:How does infigratinib's profile compare to injectables in achondroplasia?
A:Infigratinib offers a daily oral option with a best-in-class profile, including the largest AHV change, proportionality improvement, and a differentiated safety profile. Historical benchmarks suggest oral options can expand markets by 3-4x within five years of launch.
Q:What is the status of the PROPEL Infant and Toddler study for infigratinib?
A:There is significant excitement from sites due to the efficacy shown in the PROPEL 3 data. Management will provide updates on timing as the program progresses.
Q:What is the company's strategy for sustaining its R&D engine and pipeline development?
A:The focus is on executing current opportunities, including three product launches and additional indications for existing drugs. They are also prosecuting internal programs in ADPKD, dilated cardiomyopathy, and ATTR cardiomyopathy. Sister companies like GondolaBio are advancing additional genetic disease programs.
Q:What is driving the growth in new patient starts for ATTR cardiomyopathy?
A:Growth is driven by improved algorithms in EMRs, genetic testing in variant-heavy populations, and physician education. However, there are challenges like the PYP shortage for diagnostic scans, which management is monitoring.
Q:How is encaleret positioned in chronic hypoparathyroidism compared to PTH replacement therapies?
A:Encalaeret offers an oral option that normalizes both blood and urine calcium, avoiding potential safety risks associated with PTH therapies. Management believes it can compete effectively and gain a reasonable market share.
Q:What commercial preparations are being made for infigratinib in achondroplasia?
A:The company has built strong commercial and medical leadership with experience in skeletal dysplasia and oral launches. They are focusing on educating community pediatric endocrinologists and broader awareness efforts.
Q:What role do patient advocacy groups play in the development of infigratinib for achondroplasia?
A:Advocacy groups have been integral in shaping the development program and endpoints, ensuring alignment with patient and family needs. They are expected to remain key partners through commercialization.
Q:Review of Unclear Management Responses
A:Management avoided directly answering whether they would run a double-blind head-to-head study for acoramidis versus tafamidis, citing challenges in sizing a hospitalization study and the lack of obvious opportunities. They also provided limited details on the timing for the PROPEL Infant and Toddler study for infigratinib, stating only that updates would come later.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADH LGMDI
NPV
Phase III
acoramidis tafamidis
activity quality
approval launch
balance sheet
benefit acoramidis
buyback
differentiation
discipline
end
evidence study
excess
excitement
family
improvement
increase investment
increase sale
line presentation
loss quarter
matter
model value
mortality value
outperformance
people
publication
reauthorization
repurchase program
share repurchase
share today
solution
submission
talk
term value
testing
today investor
value creation
value investor
value share
world evidence
BBIO Transcript
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary and Q&A reveal positive sentiment: strong projections for Attruby, a $500M share repurchase, and positive feedback on infigratinib. The company is gearing up for multiple product launches and has a solid market strategy. Despite some vague responses, the overall outlook is promising, with a focus on growth and shareholder returns. The market cap suggests moderate volatility, leading to a positive stock price movement prediction.
BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call showed strong financial performance with significant revenue growth and promising drug trials. Attruby's market share is expanding, and the company has a solid cash position. Despite increased operating expenses, the focus on organic growth and potential shareholder returns is favorable. The Q&A highlighted management's confidence in sustained growth and strategic use of cash. The market cap suggests a moderate reaction, leading to a positive outlook for the stock price.
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
Neutral1-12
BBIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
